Lysine 48-Linked Polyubiquitination of Organic Anion Transporter-1 Is Essential for Its Protein Kinase C–Regulated Endocytosis

Qiang Zhang, Shanshan Li, Cam Patterson, and Guofeng You

Department of Pharmaceutics, Rutgers, the State University of New Jersey, Piscataway, New Jersey (Q.Z., S.L., G.Y.); Department of Pharmacology, UMDNJ Robert Wood Johnson Medical School, Piscataway, New Jersey (G.Y.); and McAllister Heart Institute, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina (C.P.)

Received August 23, 2012; accepted October 19, 2012

ABSTRACT

Organic anion transporter-1 (OAT1) mediates the body’s disposition of a diverse array of environmental toxins and clinically important drugs. Therefore, understanding the regulation of this transporter has profound clinical significance. We had previously established that OAT1 undergoes constitutive internalization from and recycling back to the cell surface and that acute activation of protein kinase C (PKC) inhibits OAT1 activity by reducing OAT1 cell-surface expression through accelerating its internalization from cell surface to intracellular compartments. However, the underlying mechanisms are poorly understood. In the current study, we provide novel evidence that acute activation of PKC significantly enhances OAT1 ubiquitination both in vitro and ex vivo. We further show that ubiquitination of cell-surface OAT1 increases in cells transfected with dominant negative mutant of dynamin-2, a maneuver blocking OAT1 internalization, which suggests that OAT1 ubiquitination proceeds before OAT1 internalization. Mass spectroscopy has revealed that ubiquitination of OAT1 consists of polyubiquitin chains, primarily through lysine 48 linkage. Transfection of cells with the dominant negative mutant of ubiquitin Ub-K48R, which prevents the formation of Lys48-linked polyubiquitin chains, abolishes PKC-stimulated OAT1 ubiquitination and internalization. Together, our findings demonstrate for the first time that Lys48-linked polyubiquitination is essential for PKC-regulated OAT1 trafficking.

Introduction

The organic anion transporter (OAT) family mediates the body’s disposition of a diverse array of environmental toxins and clinically important drugs, including anti-HIV therapeutics, antitumor drugs, antibiotics, antihypertensives, and anti-inflammatories (You, 2002; Dantzler and Wright, 2003; Srimaroeng et al., 2008; Ahn and Nigam, 2009; VanWert et al., 2010). Therefore, understanding the regulation of these transporters has profound clinical significance.

Ten OATs (OAT1–10) have been cloned, and their expressions have been identified in distinct tissues and cell membranes. In the kidney, OAT1 and OAT3 use a tertiary transport mechanism to move organic anions across the basolateral membrane into the proximal tubule cells for subsequent exit across the apical membrane into the urine for elimination. Through this tertiary transport mechanism, Na\(^+\)/K\(^+\)-ATPase maintains an inwardly directed (blood-to-cell) Na\(^+\) gradient. The Na\(^+\) gradient then drives a sodium dicarboxylate cotransporter, sustaining an outwardly directed dicarboxylate gradient that is used by a dicarboxylate/organic anion exchanger—namely, OAT—to move the organic anion substrate into the cell. This cascade of events indirectly links organic anion transport to metabolic energy and the Na\(^+\) gradient, allowing the entry of a negatively charged substrate against both its chemical concentration gradient and the electrical potential of the cell (You, 2002; Dantzler and Wright, 2003; Srimaroeng et al., 2008; Ahn and Nigam, 2009; VanWert et al., 2010).

All of the cloned OATs share several common structural features, including 12 transmembrane domains flanked by intracellular amino and carboxyl termini, multiple glycosylation sites localized in the first extracellular loop, and multiple potential phosphorylation sites. Investigations by our laboratory on the structure–function relationship of OATs have revealed that glycosylation is necessary for the targeting of these transporters to the plasma membrane (Tanaka et al., 2004).

The amount of OATs at the cell surface is critical for their drug transport activity. We previously showed that members of OAT family constitutively internalize from and recycle back to the cell surface, and that inhibition of OAT activity by acute activation of protein kinase C (PKC) results from an accelerated internalization of these transporters from the cell membrane.
surface to intracellular compartments without affecting the total expression of the transporters (Zhang et al., 2008). However, the effect of the mechanisms of PKC on OAT internalization and function is largely unknown. PKC-induced direct phosphorylation has been reported for other membrane proteins, yet our results showed that a range of PKC activators failed to elevate the phosphorylation level of OATs under various experimental conditions (You et al., 2000). This suggests that direct phosphorylation of OATs is unlikely to be the cause for PKC-induced inhibition of OAT activity.

Recently, modification of receptors and channels by ubiquitin conjugation has emerged as the major regulatory mechanism of internalization, intracellular sorting, and turnover of these membrane proteins (Miranda et al., 2005; Kumar et al., 2007; Zhou et al., 2007; Varghese et al., 2008; Bomberger et al., 2009). Ubiquitin moiety can be recognized by the components of plasma membrane internalization and endosomal sorting machinery.

Ubiquitin is a highly conserved 76-amino-acid protein that forms an isopeptide bond between its C-terminal glycine and a lysine residue on the target protein. Each ubiquitin moiety harbors seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63), allowing for the formation of ubiquitin chains linked through its internal lysine residues. Therefore, a substrate can be modified by different types of ubiquitin conjugation: mono-ubiquitination (conjugation of one single ubiquitin to one single lysine on the substrate), mult ubiquitination (conjugation of several monoubiquitin molecules to multiple lysine residues on the substrate), and polyubiquitination (extended polyubiquitin chain). In addition, a polyubiquitin chain can bear different linkages such as Lys48 linkage (Lys48 in the ubiquitin serves as a base for chain elongation) and Lys63 linkage (Lys63 in the ubiquitin serves as a base for chain elongation). It has been shown that different types and linkages of ubiquitination have different physiologic outcomes for the ubiquitinated substrate (Kolodziejski et al., 2002; Miranda et al., 2005; Kumar et al., 2007; Zhou et al., 2007; Bomberger et al., 2009). Our study investigated the role of ubiquitination in PKC-regulated OAT1 trafficking.

Materials and Methods

Membrane impermeable biotinylation reagent NHS-SS-biotin and streptavidin agarose beads were purchased from Pierce (Rockford, IL). COS-7 cells and Dynamin (Dyn)-2/K44A mutant were purchased from the American Type Culture Collection (Manassas, VA). cDNA for hemagglutinin (HA)-tagged target ubiquitin HA-UbA2G was generously provided by Dr. N. Tony Eissa of the Department of Medicine, Baylor College of Medicine, Houston, TX. cDNAs for HA-tagged wild-type ubiquitin and HA-tagged ubiquitin mutants HA-K48R and HA-K63R were generously provided by Dr. Cam Patterson of the Carolina Cardiovascular Biology Center, University of North Carolina (Chapel Hill, NC). Mouse anti-ubiquitin antibody (9E10) and mouse anti-HA antibody 12CA5 were purchased from Roche Diagnostics Corporation (Indianapolis, IN). Mouse anti-ubiquitin antibody P4D1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-ubiquitin antibody FK2 was purchased from Enzo Life Sciences (Farmingdale, NY). PKC activator phorbol 12-myristate 13-acetate (PMA) and all other reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Cell Cultures. COS-7 cells stably expressing human OAT1 (tagged with epitope myc at its carboxyl terminus for immunodetection) (Zhang et al., 2008) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 0.2 mg/ml G418, 10% fetal bovine serum, penicillin/streptomycin (100 U/ml), and glucose (100 mg/ml).

Ubiquitination Assay. Cells expressing OAT1-myc were treated with dimethyl sulfoxide (DMSO) or 1 μM PMA at 37°C for indicated time periods. Treated cells were lysed with lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA, and 1 mM NaF) freshly added with 1% of protease inhibitor cocktail and 20 mM N-ethylmaleimide (a deubiquitination inhibitor). OAT1 was then immunoprecipitated with anti-myc antibody, followed by immunoblotting with anti-ubiquitin antibody P4D1 or anti-myc antibody 9E10.

Preparation of Rat Kidney Slices. Male Sprague-Dawley rats were euthanized by CO2 inhalation, and the kidneys were immediately placed into freshly oxygenated ice-cold saline. Tissue slices (<0.5 mm; 5–10 mg wet weight) were cut with a Stadie-Riggs microtome and maintained in ice-cold modified Cross and Taggart saline (95 mM NaCl, 80 mM mannitol, 5 mM KC1, 0.74 mM CaCl2, and 9.5 mM Na2PO4, pH 7.4) for ubiquitination studies.

Cell Surface Biotinylation. The cell-surface expression level of OAT1 was examined using the membrane-impermeable biotinylation reagent NHS-SS-biotin. Cells were plated in six-well plates. Each well of cells was incubated with 1 ml of NHS-SS-biotin (0.5 mg/ml in phosphate-buffered saline (PBS)) in two successive 20-minute incubations on ice with very gentle shaking. The reagent was freshly prepared each time. After biotinylation, each well was briefly rinsed with 3 ml of PBS/CM containing 100 mM glycine then incubated with the same solution for 30 minutes on ice to ensure complete quenching of the unreacted NHS-SS-biotin. The cells were then lysed on ice for 1 hour in 400 μl of lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100 with 1/100 protease inhibitor cocktail). The cell lysates were cleared by centrifugation at 16,000g at 4°C. We then added 50 μl of streptavidin-agarose beads to the supernatant to isolate cell membrane proteins. OAT1 was detected in the pool of surface proteins by immunoblotting using an anti-myc antibody 9E10.

To determine ubiquitinated OAT1 in the biotinylated protein fraction, cell-surface proteins were biotinylated. OAT1 was immunoprecipitated with anti-myc antibody. Immunoprecipitated proteins were eluted from the beads with 1% SDS (37°C, 15 minutes). Next, SDS was diluted to 0.1%, and the eluted OAT1 proteins were incubated with streptavidin-agarose beads, followed by immunoblotting using anti-ubiquitin antibody P4D1 or anti-myc antibody.

Internalization Assay. For the internalization assay, we followed the procedure previously established in our laboratory (Zhang et al., 2008). OAT1-expressing cells underwent biotinylation with 0.5 mg/ml sufo-NHS-SS-biotin at 4°C. Following biotinylation, OAT1 internalization was initiated by incubating the cells (37°C) in PBS containing either 1 μM PMA or vehicle for designated periods of time. Residual cell-surface biotin was stripped by incubating cells 3 times for 2 minutes with freshly prepared 50 mM MesNa in NT buffer (150 mM NaCl, 1 mM EDTA, 0.2% bovine serum albumin, 20 mM Tris, pH 8.6). Cells were lysed in lysis buffer with protease inhibitor cocktail. Biotinylated (internalized) proteins were separated from nonbiotinylated proteins by streptavidin pull-down from equivalent amounts of cellular proteins, followed by immunoblotting with anti-myc antibody.

Purification of Ubiquitinated OAT1 by Sequential Immunoprecipitation. Six 10-cm-diameter dishes of COS-7 cells expressing OAT1 were treated with 1 μM PMA for 30 minutes at 37°C. Treated cells were solubilized with lysis buffer I with 3% protease inhibitor cocktail and 40 mM N-ethylmaleimide. The cell lysate was precleared with protein G-agarose for 2 hours at 4°C, followed by immunoprecipitation with anti-myc antibody that was cross-linked to protein G beads with dimethyl pimelimidate (Pierce). After an extensive wash with lysis buffer I containing 500 mM NaCl, the immunoprecipitated proteins were eluted with 1% SDS and...
immunoprecipitated again with anti-ubiquitin antibody FK2, which was cross-linked to protein G beads with dimethyl pimelimidate. After the second immunoprecipitation, 10% of precipitated proteins were analyzed by immunoblotting with anti-ubiquitin antibody P4D1 or anti-myc antibody, and 90% by Coomassie Blue staining.

**Protein Identification by Liquid Chromatography–Tandem Mass Spectrometry.** The gel bands of interest were reduced, carboxymethylated with iodoacetamide, digested with trypsin. Peptides were extracted, solubilized in 0.1% trifluoroacetic acid, and analyzed by nano-liquid chromatography–tandem mass spectrometry (LC-MS/MS) using a rapid separation liquid chromatography system ( Dionex, Sunnyvale, CA) interfaced with a Velos-LTQ-Orbitrap (Thermo Fisher Scientific, San Jose, CA). Samples were loaded onto a self-packed 100 μm × 2 cm trap packed with Magic C18AQ, 5-μm 200 A (Michrom Bioresources Inc., Auburn, CA) and washed with buffer A (0.2% formic acid) for 5 minutes with flow rate of 10 μL/min. The trap was brought in line with the homemade analytical column (Magic C18AQ, 3 μm 200 A, 75 μm × 50 cm), and peptides were fractionated at 300 nL/min with a 90-minute linear gradient of 2 to 45% buffer B (0.2% formic acid, acetonitrile). Mass spectrometry data were acquired using a data-dependent acquisition procedure, with a cyclic series of a full scan acquired in Orbitrap with resolution of 60,000 followed by MS/MS scans (acquired in linear ion trap) of 20 most intense ions with a repeat count of two and the dynamic exclusion duration of 60 seconds.

The LC-MS/MS data were searched against the ENSEMBL human database using a local version of the Global Proteome Machine (GPM USB; Beavis Informatics Ltd, Winnipeg, MB, Canada) with carbamidomethyl on cysteine as the fixed modification and ubiquitination on lysine (±114 Da) as well as oxidation of methionine and tryptophan as the variable modifications using a 10-ppm precursor ion tolerance and a 0.4-Da fragment ion tolerance. Polyubiquitin sites were identified on ubiquitin lysine residues.

**Electrophoresis and Immunoblotting.** Protein samples were resolved on 7.5% SDS-PAGE minigels and electroblotted on to polyvinylidene difluoride membranes. The blots were blocked for 1 hour with 5% nonfat dry milk in PBS-0.05% Tween-20, washed, and incubated for 1 hour at room temperature with appropriate primary antibodies followed by horseradish peroxidase–conjugated secondary antibodies. The signals were detected by the SuperSignal West Dura (Pierce). Nonsaturating, immunoreactive protein bands were quantified by scanning densitometry with Extended Duration Substrate kit (Pierce). Nonsaturating, immunoreactive protein bands were quantified by scanning densitometry with Extended Duration Substrate kit (Pierce).

**Data Analysis.** Each experiment was repeated a minimum of three times. The statistical analysis was from multiple experiments. Statistical analysis was performed using Student’s paired t tests. P < 0.05 was considered statistically significant.

**Results**

**PKC-Induced Ubiquitination of OAT1 by Endogenous Ubiquitin.** To examine whether OAT1 undergoes ubiquitination, COS-7 cells stably expressing OAT1 were treated with or without PMA, a PKC activator, for different periods of time. OAT1 was then immunoprecipitated by anti-myc antibody (myc was tagged to OAT1), followed by immunoblotting with anti-ubiquitin antibody. As shown in Fig. 1A, OAT1 ubiquitination was barely detectable under the basal condition. Interestingly, PMA treatment induced a time-dependent ubiquitination of the transporter with maximum ubiquitination around 15 to 30 minutes. Moreover, when the immunoblot was probed with anti-myc antibody, it was shown that these short-term treatments did not produce any major change in the amount of OAT1 (Fig. 1B).

The PMA-induced OAT1 ubiquitination was blocked by staurosporine, a general PKC inhibitor (Fig. 2A), without affecting the total amount of OAT1 (Fig. 2B), demonstrating the specific involvement of PKC in OAT1 ubiquitination. The ubiquitin-immunoreactive signal displayed a smeary band centered ~140 kDa, ~60 kDa larger than the size of OAT1 (~80 kDa). Given that each ubiquitin molecule is ~8 kDa, OAT1 most likely is either mult ubiquitinated or polyubiquitinated.

A similar experiment was then performed with rat kidney slices (Fig. 3). Upon PMA treatment, dramatic increase of OAT1 ubiquitination was detected. Again, such ubiquitination was blocked by PKC inhibitor staurosporine (Fig. 3A).

These results suggest that OAT1, regardless of species origin, undergoes PKC-regulated ubiquitination both in cultured cells and in rat kidney tissue.

**PKC-Induced Ubiquitination of OAT1 by Ectopically Expressed Ubiquitin.** OAT1-expressing cells were transiently transfected with HA-tagged ubiquitin. Transfected cells were treated with PMA in the presence and absence of staurosporine, a general PKC inhibitor (Fig. 2A), without affecting the total amount of OAT1 (Fig. 2B), demonstrating the specific involvement of PKC in OAT1 ubiquitination. The ubiquitin-immunoreactive signal displayed a smeary band centered ~140 kDa, ~60 kDa larger than the size of OAT1 (~80 kDa). Given that each ubiquitin molecule is ~8 kDa, OAT1 most likely is either mult ubiquitinated or polyubiquitinated.

A similar experiment was then performed with rat kidney slices (Fig. 3). Upon PMA treatment, dramatic increase of OAT1 ubiquitination was detected. Again, such ubiquitination was blocked by PKC inhibitor staurosporine (Fig. 3A).

These results suggest that OAT1, regardless of species origin, undergoes PKC-regulated ubiquitination both in cultured cells and in rat kidney tissue.
PKC inhibitor staurosporine. OAT1 was then immunoprecipitated, followed by immunoblotting with anti-HA antibody (to detect HA-tagged ubiquitin). The HA immunoreactivity was dramatically increased in the samples treated with PMA, and was significantly decreased in the presence of staurosporine (Fig. 4A), indicating that the conjugation of HA-ubiquitin to OAT1 is PKC-dependent.

**OAT1 Ubiquitination at the Cell Surface.** To determine whether OAT1 ubiquitination occurs at the cell surface, we developed a two-step procedure to ensure that only cell-surface OAT1 ubiquitination was detected (Fig. 5A). Briefly, cell surface proteins were labeled with or without the membrane-impermeable reagent NHS-SS-biotin. Labeled cells were lysed. OAT1 was then immunoprecipitated, with subsequent streptavidin pull-down to isolate cell surface OAT1. Immunoblotting of this streptavidin pull-down with anti-ubiquitin antibody showed no signal for ubiquitin in cells not labeled with biotin. However, in cells labeled with biotin, the ubiquitin signal dramatically increased in the presence of PMA. This result demonstrated that the two-step procedure detected only cell surface OAT1 ubiquitination.

Using this procedure, we next examined the effect of a dominant negative mutant of dynamin-2 (Dyn-2m) on OAT1 ubiquitination. We previously had demonstrated that OAT1 internalization occurred partly through a Dyn- and clathrin-dependent pathway and that such internalization was blocked in cells transfected with a Dyn-2m. As a result, OAT1 accumulated at the cell surface (Zhang et al., 2008). In the current experiment, we transfected OAT1-expressing cells with Dyn-2m (or empty vector as control). Transfected cells were treated with PMA for 30 minutes, and cell surface proteins were biotinylated, followed by the same procedure shown in Fig. 5A for the detection of cell-surface OAT1 ubiquitination. Our results showed that ubiquitinated OAT1 was significantly elevated in cells transfected with Dyn-2m (Fig. 5, B and C), a maneuver that blocked OAT1 internalization. These data indicate that OAT1 is preferentially ubiquitinated when present at the cell surface and that ubiquitination of OAT1 precedes its internalization.

**Identification of Ubiquitination Linkage of OAT1.** As mentioned previously, different types of ubiquitination (mono- versus polyubiquitination via different types of linkages) have different physiologic outcomes for the ubiquitinated substrate. To identify the ubiquitination type of OAT1, we employed a sequential immunoprecipitation procedure to purify ubiquitinated OAT1. Briefly, we treated OAT1-expressing cells with the PKC activator PMA for 30 minutes. Treated cells were then lysed. OAT1 was then immunoprecipitated, followed by a second immunoprecipitation using ubiquitin-specific antibody to purify ubiquitinated OAT1 (normal IgG as negative control). The ubiquitinated OAT1 was then separated on SDS-PAGE, followed by Coomassie Blue-staining. A Coomassie Blue-stained broad band centered ∼140 kDa was dissected for mass spectrometric analysis, and a sufficient amount of information regarding the peptides that originated from ubiquitin sequences was obtained. Among various peptides identified from ubiquitin, which cover all its seven lysine residues, only Lys48-linked ubiquitin was detected (Table 1). These results indicate that OAT1 is ubiquitinated mainly through Lys48-linked polyubiquitin chains.

**The Role of Lys48-Linked Polyubiquitin Chains in PKC-Regulated OAT1 Ubiquitination.** To explore the role of Lys48-linked polyubiquitin chains in PKC-regulated OAT1 ubiquitination, we employed four HA-tagged-ubiquitin constructs: wild-type ubiquitin Ub; mutant ubiquitin UbK48R (Kolodziejski et al., 2002), which has the C-terminal Gly residue deleted and therefore prevents the conjugation of ubiquitin to OAT1; mutant ubiquitin Ub-K63R (Li et al., 2007), which has the invariant Lys in position 63 mutated to Arg and prevents the formation of Lys48-linked polyubiquitin chains; and mutant ubiquitin Ub-K63R (Li et al., 2007), which has the invariant Lys in position 63 mutated to Arg and prevents the formation of Lys63-linked polyubiquitin chains. The cDNA encoding these ubiquitin constructs were transfected into OAT1-expressing cells. The transfected cells were treated with or without PMA. OAT1 was then immunoprecipitated, followed by immunoblotting with anti-HA antibody. Our results (Fig. 6) showed that PMA treatment resulted in a strong HA-immunoreactive signal in both Ub- and Ub-
The OAT family mediates the body disposition of a diverse array of environmental toxins and clinically important drugs. Therefore, understanding the regulation of these transporters has profound clinical significance. Short-term (acute) regulation of OAT activity is particularly important when the body must deal with rapidly changing amounts of substances as a consequence of variable intake of drugs, fluids, and meals as well as metabolic activity.

The amount of OATs at the cell surface is critical for their drug transport activity. We previously had established that OAT1 undergoes constitutive internalization from and recycling back to the cell surface and that acute activation of PKC inhibits OAT1 activity by reducing OAT1 cell-surface expression through accelerating its internalization from the cell surface to intracellular compartments without affecting the recycling and the total expression of the transporter (Zhang et al., 2008). Owing to this characteristic, PKC inhibition of OAT1 activity is usually moderate (30–50%) because there is always a certain amount of OAT1 at the cell surface resulting from the recycling, even with the maximum stimulation of PKC. In vivo, regulation at such a moderate scale may play an important role in providing quick and efficient fine-tuning in the body’s response to environmental changes. However, the mechanisms underlying PKC-regulated OAT1 trafficking are largely unknown. In our current study, we provide the first demonstration that a topology-specific polyubiquitination of OAT1 plays an essential role in this process.

We first examined OAT1 ubiquitination in COS-7 cells stably expressing this transporter. Although native systems that endogenously express transporters are great assets to identify the endogenous stimuli controlling the transporter function, heterologous expression systems are useful for asking mechanistic questions with regard to understanding the relationship between transporter trafficking and regulation. COS-7 cells offer several useful advantages for study of these transporters. 1) These cells were directly derived from the cloned OAT. 2) They possess endogenous PKC and PKA signaling pathways and provide a good experimental model of other OATs. 3) They are stably expressing this transporter. Although native systems that endogenously express transporters are great assets to identify the endogenous stimuli controlling the transporter function, heterologous expression systems are useful for asking mechanistic questions with regard to understanding the relationship between transporter trafficking and regulation. COS-7 cells offer several useful advantages for study of these transporters.
We previously had demonstrated that OAT1 internalizes partly through a Dyn- and clathrin-dependent pathway and that such internalization was blocked in cells transfected with a dominant negative mutant of Dyn-2. As a result, OAT1 accumulated at the cell surface (You et al., 2000). In our current study, we show (Fig. 5) that blocking OAT1 internalization with dominant negative mutant of Dyn-2 correlates with the accumulation of ubiquitinated OAT1 in the plasma membrane, suggesting that ubiquitination is an early event that occurs at the cell surface before OAT1 internalization.

It has been shown that different types of ubiquitination (mono- versus polyubiquitination via different types of linkages) have different physiologic outcomes for the ubiquitinated substrate. For example, while monoubiquitination is required for down-regulation of the epidermal growth factor receptor (EGF) receptor (Haglund et al., 2003a, 2003b), Lys63-linked ubiquitin chains have been shown to contribute to endocytosis of the TrkA nerve growth factor receptor (Geetha et al., 2005). Although IFNAR1 internalization requires both Lys48 and Lys63 linkages, PRLr internalization relies mainly on Lys63-conjugated chains (Kumar et al., 2007; Varghese et al., 2008). To identify the specific types of OAT1 ubiquitination, we performed mass spectrometric analysis, one of the most powerful approaches to identify post-translational modifications of numerous proteins. For this purpose, we developed sequential immunoprecipitation procedures to ensure that a high purity of ubiquitinated OAT1 was used. The mass spectrometric results indeed confirmed that ubiquitin and OAT1 were the two predominant proteins detected in our sample, providing evidence that ubiquitin was conjugated to OAT1 rather than to an OAT1-associated protein. Furthermore, our mass spectrometric analysis identified several peptide fragments from ubiquitin protein, which covered all its seven lysine residues. Among these fragments, only Lys48-linked ubiquitin was detected (Table 1). These results indicate that OAT1 is ubiquitinated mainly through Lys48-linked polyubiquitin chains.

The mass spectrometric data that OAT1 was ubiquitinated mainly through Lys48-linked polyubiquitin chains was independently confirmed through the use of a series of ubiquitin mutants (Fig. 6). The mutant Ub-K63R, which is defective in forming Lys63-linked polyubiquitin chains, incorporated into OAT1 as efficiently as that of wild-type ubiquitin, whereas mutant Ub-K48R, which is defective in forming Lys48-linked polyubiquitin chains, had the minimum incorporation into OAT1. The strong evidence of the importance of Lys48-linked polyubiquitination for OAT1 trafficking came from our studies using dominant negative ubiquitin mutant Ub-K48R. Interfering with Lys48-linked polyubiquitination impeded the PKC-induced down-regulation of OAT1 surface.
expression (Fig. 7) and the PKC-accelerated OAT1 internalization (Fig. 8).

It is important to note that our entire study investigated the role of ubiquitination in short-term PKC regulation (PMA treatment of 30 minutes) on OAT1 trafficking and function. We had previously demonstrated (Zhang et al., 2008) that short-term treatment of OAT1-expressing cells with PMA (30 minutes) inhibits OAT1-mediated transport by reducing OAT1 cell-surface expression through accelerating its internalization from the cell surface to intracellular compartments without affecting the total expression of the transporter, suggesting that degradation of OAT1 (through either proteasome or lysosome) does not happen during the 30 minutes of PMA treatment. This is similar to several other ubiquitination-regulated proteins for which ubiquitination regulates endocytosis without affecting their degradation (Mukhopadhyay and Riezman, 2007). It would be really interesting to explore, in the future, whether long-term treatment with PMA (2 to 8 hours) would affect OAT1 degradation.

In conclusion, ubiquitination has been shown to regulate internalization, postinternalization sorting, and degradation of other membrane proteins. Our current investigation focuses on the first step: internalization. The major findings from our studies are (Fig. 9) that 1) activation of PKC promotes OAT1 ubiquitination both in vitro and ex vivo, 2) OAT1 ubiquitination mainly occurs at the cell surface through Lys48-linked polyubiquitin chains, and 3) Lys48-linked polyubiquitination plays an essential role in PKC-regulated OAT1 trafficking.

To the best of our knowledge, this report is the first mechanistic study to demonstrate a topology-specific role of
ubiquitin in the regulation of any drug transporters. What would be the physiologic implication of our studies? Abnormal OAT1 trafficking may contribute to the impaired drug elimination in bilateral ureteral obstruction (BUO). BUO is a serious and common clinical condition, and an important cause of acute renal failure (Seldin and Giebisch, 2000; Villar et al., 2005). It has been shown (Villar et al., 2005) that in rats with BUO the elimination of drugs is impaired, partly due to a redistribution of OAT1 from the cell surface to the intracellular compartment. In BUO, angiotensin II has an elevated level of expression (Klahr, 1998; Klahr and Morrissey, 2002; Seldin and Giebisch, 2000). We previously reported that angiotensin II inhibits OAT1 activity through activation of PKC in cultured cells (Li et al., 2009). Therefore, the high level of angiotensin II in rats with BUO may inhibit OAT1 activity through PKC-regulated OAT1 ubiquitination and trafficking. Our current studies may provide important insight into the molecular, cellular, and clinical bases underlying BUO.

Finally, while the limited coverage of OAT1-derived peptides did not allow us to identify the ubiquitin-accepting lysine residues on OAT1 using mass spectrometry, while the current manuscript was being reviewed we reported to a different approach—site-directed mutagenesis—and we succeeded in identifying three lysine residues on OAT1 that serve as ubiquitin acceptors (a separate manuscript has been submitted). Our work paves the way for the investigation of the ubiquitin regulation of other OAT isoforms and related drug transporters.

Authorship Contributions

Participated in research design: Zhang, You.

Contributed reagents: Patterson.

Conducted experiments: Zhang, Li.

Performed data analysis: Zhang, You.

Wrote or contributed to the writing of the manuscript: Zhang, You.

References


Address correspondence to: Dr. Guofeng You, Department of Pharmacaceutics, Rutgers, the State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854. E-mail: gyou@rci.rutgers.edu